Evolus boasts early resubmission of FDA-rejected Botox alternative
Three months after the US FDA vetoed Evolus’ Botox alternative, the firm has announced its resubmission of DWP-450 for approval.
Archives for August 10, 2018
Amgen begins work on $200m ‘next-gen’ biomanufacturing site
Amgen has broken ground on the construction of its West Greenwich, Rhode Island-based 120,000-square-foot biomanufacturing facility.
DNA damage from CRISPR/Cas9 editing could lead to cancer, finds report
Gene editing with CRISPR/Cas9 can cause genetic damage to cells leading to possible cancer risks, the study reported.